Huntington National Bank Lowers Position in Edwards Lifesciences Co. (NYSE:EW)

Huntington National Bank lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 8.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 221,147 shares of the medical research company's stock after selling 20,919 shares during the quarter. Huntington National Bank's holdings in Edwards Lifesciences were worth $14,594,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of EW. Crewe Advisors LLC bought a new stake in Edwards Lifesciences in the first quarter worth about $28,000. First Community Trust NA purchased a new position in Edwards Lifesciences in the second quarter valued at approximately $29,000. Webster Bank N. A. bought a new position in Edwards Lifesciences during the second quarter valued at $39,000. Peoples Bank KS purchased a new stake in Edwards Lifesciences in the third quarter worth $40,000. Finally, Versant Capital Management Inc raised its stake in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company's stock valued at $45,000 after buying an additional 326 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Price Performance

NYSE EW traded up $1.60 on Friday, reaching $67.76. 6,390,391 shares of the company's stock traded hands, compared to its average volume of 4,640,860. The stock has a market cap of $39.96 billion, a PE ratio of 9.58, a P/E/G ratio of 3.74 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a 50-day simple moving average of $67.42 and a 200 day simple moving average of $76.37.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm's revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.59 earnings per share. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on EW shares. Baird R W lowered Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Edwards Lifesciences from $103.00 to $85.00 and set a "buy" rating on the stock in a research report on Thursday, July 25th. Jefferies Financial Group downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating and cut their price objective for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. UBS Group reduced their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating for the company in a research note on Tuesday, September 10th. Finally, Evercore ISI cut their price target on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating for the company in a report on Tuesday, October 1st. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $75.67.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the company's stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company's stock, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,250 shares of company stock valued at $2,744,438 in the last ninety days. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.